View Item 

Show simple item record

The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients

dc.contributor.authorMoukarbel, George V.en_US
dc.contributor.authorYu, Zi‐fanen_US
dc.contributor.authorDickstein, Kennethen_US
dc.contributor.authorHou, Yingxin (Rachel)en_US
dc.contributor.authorWittes, Janet T.en_US
dc.contributor.authorMcMurray, John J. V.en_US
dc.contributor.authorPitt, Bertramen_US
dc.contributor.authorZannad, Faiezen_US
dc.contributor.authorPfeffer, Marc A.en_US
dc.contributor.authorSolomon, Scott D.en_US
dc.date.accessioned2014-03-05T18:18:55Z
dc.date.available2015-04-16T14:24:20Zen_US
dc.date.issued2014-03en_US
dc.identifier.citationMoukarbel, George V.; Yu, Zi‐fan ; Dickstein, Kenneth; Hou, Yingxin (Rachel); Wittes, Janet T.; McMurray, John J. V.; Pitt, Bertram; Zannad, Faiez; Pfeffer, Marc A.; Solomon, Scott D. (2014). "The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27â 610 patients." European Journal of Heart Failure 16(3): 289-299.en_US
dc.identifier.issn1388-9842en_US
dc.identifier.issn1879-0844en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/106080
dc.publisherJohn Wiley & Sons, Ltden_US
dc.subject.otherG Lomerular Filtration Rateen_US
dc.subject.otherM Yocardial Infarctionen_US
dc.subject.otherC Ardiovascular Outcomesen_US
dc.subject.otherK Idney Functionen_US
dc.titleThe impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patientsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelCardiovascular Medicineen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/106080/1/ejhf11.pdf
dc.identifier.doi10.1002/ejhf.11en_US
dc.identifier.sourceEuropean Journal of Heart Failureen_US
dc.identifier.citedreferencePitt B, Williams G, Remme W, Martinez F, Lopez‐Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post‐AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001; 15: 79 – 87.en_US
dc.identifier.citedreferenceAstor BC, Hallan SI, Miller ER III, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all‐cause mortality in the US population. Am J Epidemiol 2008; 167: 1226 – 1234.en_US
dc.identifier.citedreferenceManjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47 – 55.en_US
dc.identifier.citedreferenceMeisinger C, Doring A, Lowel H. Chronic kidney disease and risk of incident myocardial infarction and all‐cause and cardiovascular disease mortality in middle‐aged men and women from the general population. Eur Heart J 2006; 27: 1245 – 1250.en_US
dc.identifier.citedreferenceNational Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 Suppl 1: S1 – S266.en_US
dc.identifier.citedreferenceNewsome BB, Warnock DG, McClellan WM, Herzog CA, Kiefe CI, Eggers PW, Allison JJ. Long‐term risk of mortality and end‐stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med 2008; 168: 609 – 616.en_US
dc.identifier.citedreferenceParikh CR, Coca SG, Wang Y, Masoudi FA, Krumholz HM. Long‐term prognosis of acute kidney injury after acute myocardial infarction. Arch Intern Med 2008; 168: 987 – 995.en_US
dc.identifier.citedreferenceAnavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285 – 1295.en_US
dc.identifier.citedreferenceDickstein K, Bebchuk J, Wittes J. The high‐risk myocardial infarction database initiative. Prog Cardiovasc Dis 2012; 54: 362 – 366.en_US
dc.identifier.citedreferencePfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893 – 1906.en_US
dc.identifier.citedreferencePitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309 – 1321.en_US
dc.identifier.citedreferenceDickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high‐risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752 – 760.en_US
dc.identifier.citedreferenceDargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left‐ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385 – 1390.en_US
dc.identifier.citedreferenceDargie HJ. Design and methodology of the CAPRICORN trial—a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail 2000; 2: 325 – 332.en_US
dc.identifier.citedreferenceDickstein K, Kjekshus J. Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 2001; 87: 766 – 771.en_US
dc.identifier.citedreferencePfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van De Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, Velazquez E, Califf R. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000; 140: 727 – 750.en_US
dc.identifier.citedreferenceLevey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461 – 470.en_US
dc.identifier.citedreferenceLevey AS, Greene T, Kusek JW, Beck GL, Group MS. A simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 2000; 11: 155A.en_US
dc.identifier.citedreferenceWright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, Miller WL, Murphy JG, Kopecky SL, Jaffe AS. Acute myocardial infarction and renal dysfunction: a high‐risk combination. Ann Intern Med 2002; 137: 563 – 570.en_US
dc.identifier.citedreferenceSchiele F, Legalery P, Didier K, Meneveau N, Seronde MF, Caulfield F, Ducloux D, Bechetoille P, Magnin D, Faivre R, Bassand JP. Impact of renal dysfunction on 1‐year mortality after acute myocardial infarction. Am Heart J 2006; 151: 661 – 667.en_US
dc.identifier.citedreferenceInrig JK, Gillespie BS, Patel UD, Briley LP, She L, Easton JD, Topol E, Szczech LA. Risk for cardiovascular outcomes among subjects with atherosclerotic cardiovascular disease and greater‐than‐normal estimated glomerular filtration rate. Clin J Am Soc Nephrol 2007; 2: 1215 – 1222.en_US
dc.identifier.citedreferenceCardarelli F, Bellasi A, Ou FS, Shaw LJ, Veledar E, Roe MT, Morris DC, Peterson ED, Klein LW, Raggi P. Combined impact of age and estimated glomerular filtration rate on in‐hospital mortality after percutaneous coronary intervention for acute myocardial infarction (from the American College of Cardiology National Cardiovascular Data Registry). Am J Cardiol 2009; 103: 766 – 771.en_US
dc.identifier.citedreferenceBurns RJ, Gibbons RJ, Yi Q, Roberts RS, Miller TD, Schaer GL, Anderson JL, Yusuf S. The relationships of left ventricular ejection fraction, end‐systolic volume index and infarct size to six‐month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 2002; 39: 30 – 36.en_US
dc.identifier.citedreferenceHalkin A, Stone GW, Dixon SR, Grines CL, Tcheng JE, Cox DA, Garcia E, Brodie B, Stuckey TD, Mehran R, Lansky AJ. Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction. Am J Cardiol 2005; 96: 325 – 331.en_US
dc.identifier.citedreferenceMarenzi G, Moltrasio M, Assanelli E, Lauri G, Marana I, Grazi M, Rubino M, De Metrio M, Veglia F, Bartorelli AL. Impact of cardiac and renal dysfunction on inhospital morbidity and mortality of patients with acute myocardial infarction undergoing primary angioplasty. Am Heart J 2007; 153: 755 – 762.en_US
dc.identifier.citedreferenceEarley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 2012; 156: 785 – 795.en_US
dc.identifier.citedreferenceCoresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038 – 2047.en_US
dc.identifier.citedreferenceSnyder JJ, Foley RN, Collins AJ. Prevalence of CKD in the United States: a sensitivity analysis using the National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 2009; 53: 218 – 228.en_US
dc.identifier.citedreferenceZhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population‐based studies: systematic review. BMC Public Health 2008; 8: 117.en_US
dc.identifier.citedreferenceSarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050 – 1065.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhf11.pdf
Size:
830.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.